S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
NASDAQ:CLSN

Imunon (CLSN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.95
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLSN stock logo

About Imunon (NASDAQ:CLSN) Stock

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.


CLSN Stock News Headlines

CLSN.L Regulatory News
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Recap: Celsion Q2 Earnings - Benzinga
See More Headlines
Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Company Calendar

Last Earnings
8/15/2022
Today
9/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Profitability

Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$9.66 per share

Miscellaneous

Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Michael H. Tardugno (Age 71)
    Exec. Chairman
    Comp: $1.01M
  • Mr. Jeffrey W. Church CPA (Age 65)
    CPA, CFO, Exec. VP & Corp. Sec.
    Comp: $528.54k
  • Dr. Khursheed Anwer M.B.A. (Age 62)
    Ph.D., Exec. VP & Chief Scientific Officer
    Comp: $511.92k
  • Dr. Nicholas Borys (Age 63)
    Exec. VP & Chief Medical Officer
    Comp: $586.54k
  • Dr. Corinne Le Goff M.B.A.
    Pharm.D., CEO, Pres & Director
  • Mr. Timothy J. Tumminello (Age 64)
    Chief Accounting Officer & Controller
  • Ms. Marianne M. Lambertson
    VP of Communications & Investor Relations













CLSN Stock - Frequently Asked Questions

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) released its earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative trailing twelve-month return on equity of 50.18% and a negative net margin of 5,229.80%. During the same period last year, the company earned ($0.90) EPS.

When did Imunon's stock split?

Imunon shares reverse split on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?
What is Imunon's stock symbol?

Imunon trades on the NASDAQ under the ticker symbol "CLSN."

How much money does Imunon make?

Imunon (NASDAQ:CLSN) has a market capitalization of $0.00 and generates $500,000.00 in revenue each year.

How can I contact Imunon?

Imunon's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The official website for the company is www.celsion.com. The biotechnology company can be reached via phone at (609) 896-9100, via email at jchurch@celsion.com, or via fax at 609-896-2200.

This page (NASDAQ:CLSN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -